Poxel (OTCMKTS:PXXLF) Rating Increased to Hold at Zacks Investment Research

Poxel (OTCMKTS:PXXLFGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Saturday, Zacks.com reports.

According to Zacks, “Poxel SA is a biopharmaceutical company. It offers drugs for metabolic diseases such as diabetes and related metabolic disorders. The company’s product pipeline consists of Imeglimin, PXL770 and PXL007 which are in clinical trial stage. Poxel SA is headquartered in Lyon, France. “

Shares of Poxel stock opened at $2.58 on Friday. The company’s fifty day simple moving average is $4.92 and its 200-day simple moving average is $5.83. Poxel has a 1-year low of $2.58 and a 1-year high of $5.83.

About Poxel (Get Rating)

Poxel SA, a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight.

See Also

Get a free copy of the Zacks research report on Poxel (PXXLF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Poxel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poxel and related companies with MarketBeat.com's FREE daily email newsletter.